{
    "medicine_id": "01a941de6053e6cb17e1c84b8fa3d20ed8d1a910",
    "platform_id": "DB02187",
    "metadata": {
        "name": "Biopar delta FORTE 150 mg Injection",
        "composition": "150 mg Equilin",
        "clinical_particulars": {
            "therapeutic_indications": "For the treatment of moderate to severe vasomotor symptoms associated with the menopause atrophic vaginitis osteoporosis hypoestrogenism due to hypogonadism castration primary ovarian failure breast cancer for palliation only and Advanced androgen dependent carcinoma of the prostate for palliation only",
            "contraindications": {
                "disease": "NA",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Equilin is a component of Premarin conjugated estrogens a mixture of the water soluble salts of sulfate esters from estrone equilin 17 alpha dihydroequilin and other related steroids may be derived from pregnant equine urine or yam and soy plants Estrogens are important in the development and maintenance of the female reproductive system and secondary sex characteristics They promote growth and development of the vagina uterus and fallopian tubes and enlargement of the breasts Indirectly they contribute to the shaping of the skeleton maintenance of tone and elasticity of urogenital structures changes in the epiphyses of the long bones that allow for the pubertal growth spurt and its termination growth of axillary and pubic hair and pigmentation of the nipples and genitals Decline of estrogenic activity at the end of the menstrual cycle can bring on menstruation although the cessation of progesterone secretion is the most important factor in the mature ovulatory cycle However in the preovulatory or nonovulatory cycle estrogen is the primary determinant in the onset of menstruation Estrogens also affect the release of pituitary gonadotropins The pharmacologic effects of conjugated estrogens are similar to those of endogenous estrogens",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB11642",
                        "description": "The serum concentration of Equilin can be decreased when it is combined with Pitolisant"
                    },
                    {
                        "drugbank-id": "DB09046",
                        "description": "The metabolism of Equilin can be increased when combined with Metreleptin"
                    },
                    {
                        "drugbank-id": "DB06119",
                        "description": "The serum concentration of Equilin can be decreased when it is combined with Cenobamate"
                    },
                    {
                        "drugbank-id": "DB00503",
                        "description": "The serum concentration of Equilin can be increased when it is combined with Ritonavir"
                    },
                    {
                        "drugbank-id": "DB00502",
                        "description": "The serum concentration of Haloperidol can be increased when it is combined with Equilin"
                    },
                    {
                        "drugbank-id": "DB11652",
                        "description": "The metabolism of Tucatinib can be decreased when combined with Equilin"
                    },
                    {
                        "drugbank-id": "DB11932",
                        "description": "The serum concentration of Equilin can be increased when it is combined with Abametapir"
                    },
                    {
                        "drugbank-id": "DB15762",
                        "description": "The serum concentration of Equilin can be decreased when it is combined with Satralizumab"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}